.After antibody-drug conjugate (ADC) professional Seagen was actually marketed to Pfizer in 2015 for...
.On the heels of a period 3 succeed that stopped working to blow away financiers, Ironwood Pharmaceu...
.Don't cease Monte Rosa Therapies right now. The Boston-based biotech is actually enjoying after sig...
.Accept to this week's Chutes & Ladders, our summary of substantial management hirings, shootings...
.Celebrating his provider's upsized initial public offering (IPO), Septerna chief executive officer ...
.AbbVie has actually gone back to the resource of its antipsychotic giant Vraylar looking for yet an...
.GenSight Biologics is weeks out of losing amount of money. Once more. The biotech merely possesses ...
.Monopar Therapies is recuperating a drug coming from the scrap heap of AstraZeneca's unusual health...
.Along with brand-new information out on Arcus Biosciences' experimental HIF-2a inhibitor, one group...
.After creating a genetics treatment relationship with Dyno Rehabs in 2020, Roche is back for additi...
.Lundbeck is actually lowering the book market value of its $250 thousand Abide Rehabs purchase in r...
.The combination of real-world information (RWD) in to protocol usefulness and also website assortme...
.At this year's Intense Biotech Top in Boston, we overtook leaders in the biotech field that have ac...
.Merck & Co. is actually putting down $30 thousand ahead of time to acquire Yale spinout Modifi B...
.Alpha-9 Oncology has actually raised a $175 million collection C cycle to bankroll its clinical-sta...
.Eye drug creator Ocuphire Pharma is acquiring gene therapy creator Piece Genetic makeup in an all-s...
.Roche's severe cough course has actually faltered to a standstill. The drugmaker, which axed the sy...
.Gilead Sciences and Merck & Co. have actually directed their once-weekly HIV blend treatment pas...
.Lykos Rehabs might possess dropped three-quarters of its workers following the FDA's being rejected...
.Septerna might be as yet to reveal "any kind of meaningful scientific records," but the biotech acc...